| Literature DB >> 22165895 |
Monica Llano-Diez1, Ann-Marie Gustafson, Carl Olsson, Hanna Goransson, Lars Larsson.
Abstract
BACKGROUND: Acute quadriplegic myopathy (AQM) or critical illness myopathy (CIM) is frequently observed in intensive care unit (ICU) patients. To elucidate duration-dependent effects of the ICU intervention on molecular and functional networks that control the muscle wasting and weakness associated with AQM, a gene expression profile was analyzed at time points varying from 6 hours to 14 days in a unique experimental rat model mimicking ICU conditions, i.e., post-synaptically paralyzed, mechanically ventilated and extensively monitored animals.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22165895 PMCID: PMC3266306 DOI: 10.1186/1471-2164-12-602
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Number of genes differentially expressed at short (0.25-4d), intermediate (5-8d) and long (9-14d) durations. Number of genes regulated at more than one time point are found in overlapping regions. Upward arrows indicate up-regulation and downward arrows indicate down-regulation.
Figure 2Results from . Genes were divided into 12 clusters using a K-means cluster analysis algorithm, which distinguishes sets of genes with similar expression profiles with respect to time. Relative expression levels (log2 ratio) for each gene and the average expression values (magenta line) are shown at different time points (0.25-4d, 5-8d and 9-14d) compared to control conditions.
Figure 3Graphical summary of significant temporal gene expression patterns according to . Red and blue arrows show up- and down-regulation, respectively. Thin arrows indicate 2- to 4-fold change and thick arrows more than 4-fold change of gene expression.
List of differentially expressed genes at least in one time point involved in signalling pathways.
| Gene Name | Gene Symbol | FC (0.25-4d) | adj.- | FC (5-8d) | adj.- | FC (9-14d) | adj.- |
|---|---|---|---|---|---|---|---|
| v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) | Akt3 | 1.1 | 7.7E-01 | 1.6 | 1.2E-02 | 2.5 | 2.9E-06 |
| insulin-like growth factor 1 receptor | Igf1r | 1.2 | 1.2E-01 | 2.0 | 2.6E-06 | 1.8 | 4.5E-06 |
| insulin-like growth factor 2 mRNA binding protein 2 | Igf2bp2 | 1.1 | 8.1E-01 | 2.2 | 4.8E-05 | 1.6 | 2.5E-03 |
| forkhead box O1 | Foxo1 | 3.1 | 3.1E-04 | 1.2 | 6.4E-01 | -1.1 | 7.0E-01 |
| insulin-like growth factor binding protein 6 | Igfbp6 | -1.2 | 7.0E-01 | -4.6 | 1.2E-04 | -2.5 | 4.8E-03 |
| insulin receptor substrate 1 | Irs1 | -1.9 | 2.9E-02 | -4.2 | 8.4E-06 | -3.9 | 2.4E-06 |
| ectodysplasin A2 receptor | Eda2r | 1.5 | 6.5E-01 | 4.7 | 8.5E-03 | 4.4 | 4.1E-03 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon | Nfkbie | 1.1 | 8.8E-01 | 2.1 | 6.2E-02 | 3.5 | 6.8E-04 |
| mitogen-activated protein kinase kinase kinase 14 | Map3k14 | 1.7 | 4.3E-01 | 3.5 | 3.0E-02 | 3.3 | 1.7E-02 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 | Nfkb2 | 1.3 | 6.5E-01 | 3.6 | 5.6E-03 | 3.1 | 5.5E-03 |
| lipopolysaccharide-induced TNF factor | Litaf | 1.7 | 4.1E-03 | 3.5 | 1.3E-07 | 3.0 | 5.2E-08 |
| mitogen-activated protein kinase kinase kinase kinase 4 | Map4k4 | 1.1 | 8.5E-01 | 3.5 | 9.4E-05 | 2.5 | 8.2E-04 |
| Tnf receptor-associated factor 2 | Traf2 | -1.0 | 1.0E+00 | 2.8 | 2.1E-03 | 2.4 | 2.4E-03 |
| interleukin-1 receptor-associated kinase 4 | Irak4 | 1.2 | 2.2E-01 | 1.6 | 1.6E-03 | 2.2 | 4.0E-07 |
| activating signal cointegrator 1 complex subunit 2 | Ascc2 | 1.4 | 1.0E-01 | 2.4 | 1.2E-04 | 2.1 | 2.8E-04 |
| TGFB-induced factor homeobox 1 | Tgif1 | 2.5 | 1.7E-03 | 5.7 | 1.1E-06 | 5.4 | 1.7E-07 |
| follistatin | Fst | 1.0 | 9.5E-01 | 1.8 | 5.5E-02 | 4.1 | 3.5E-06 |
| latent transforming growth factor beta binding protein 1 | Ltbp1 | 1.2 | 8.0E-01 | 4.2 | 2.7E-03 | 4.1 | 9.9E-04 |
| activin A receptor, type IIB | Acvr2b | -1.4 | 3.7E-02 | -1.5 | 3.7E-03 | -2.0 | 2.3E-06 |
| activin A receptor, type I | Acvr1 | -1.6 | 6.3E-03 | -2.1 | 2.2E-04 | -2.3 | 5.5E-06 |
| myostatin | Mstn | 1.8 | 1.5E-01 | -5.6 | 5.0E-05 | -3.7 | 2.8E-04 |
| signal transducer and activator of transcription 2 | Stat2 | 1.2 | 5.4E-01 | 1.8 | 5.3E-03 | 2.4 | 1.5E-05 |
| jun B proto-oncogene | Junb | 1.9 | 1.7E-01 | 1.7 | 2.0E-01 | 2.3 | 1.9E-02 |
| Janus kinase 2 | Jak2 | 1.4 | 9.8E-02 | 1.8 | 5.1E-03 | 2.2 | 6.8E-05 |
| suppressor of cytokine signaling 2 | Socs2 | -2.6 | 6.6E-06 | -3.5 | 2.9E-07 | -2.1 | 5.0E-05 |
| cytokine inducible SH2-containing protein | Cish | -3.7 | 3.9E-02 | -6.2 | 3.6E-03 | -4.6 | 5.2E-03 |
| mitogen-activated protein kinase-activated protein kinase 2 | Mapkapk2 | -1.2 | 1.4E-01 | -1.9 | 8.2E-06 | -2.2 | 4.4E-08 |
| mitogen-activated protein kinase kinase 6 | Map2k6 | -2.4 | 6.7E-02 | -9.4 | 1.6E-05 | -7.0 | 1.6E-05 |
| dual specificity phosphatase 1 | Dusp1 | -2.0 | 1.1E-01 | -4.9 | 3.0E-04 | -3.8 | 5.2E-04 |
| dual specificity phosphatase 10 | Dusp10 | -3.2 | 7.5E-05 | -1.5 | 1.3E-01 | -1.2 | 4.0E-01 |
| dual specificity phosphatase 14 | Dusp14 | -1.3 | 3.2E-01 | -2.2 | 1.9E-03 | -1.7 | 1.5E-02 |
| dual specificity phosphatase 8 | Dusp8 | -1.9 | 2.7E-03 | -4.5 | 7.8E-08 | -7.1 | 5.4E-11 |
| tumor protein p53 inducible nuclear protein 1 | Tp53inp1 | 2.6 | 2.7E-05 | 4.5 | 7.7E-08 | 3.9 | 1.2E-08 |
| nucleophosmin (nucleolar phosphoprotein B23, numatrin) | Npm1 | 1.4 | 2.4E-01 | 2.5 | 1.7E-04 | 2.5 | 5.5E-05 |
| cytoplasmic FMR1 interacting protein 2 | Cyfip2 | -1.0 | 9.9E-01 | 1.1 | 8.4E-01 | 2.1 | 3.2E-05 |
| Bri3 binding protein | Bri3bp | 1.1 | 6.2E-01 | 2.1 | 1.2E-04 | 2.1 | 1.6E-05 |
| homeodomain interacting protein kinase 2 | Hipk2 | 1.1 | 2.6E-01 | 2.0 | 8.7E-08 | 1.7 | 4.8E-07 |
| tumor protein p53 inducible nuclear protein 2 | Trp53inp2 | -1.3 | 3.6E-01 | -2.4 | 1.1E-03 | -2.2 | 1.1E-03 |
FC = fold change at the three different time points (0.25-4d, 5-8d, 9-14d) with its corresponding adjusted p-value.
Figure 4Schematic illustration of the major pathways that control adult skeletal muscle size. Significant differentially expressed genes playing important roles in these pathways were mapped according to their expression level at the three time point groups (0.25-4d, 5-8d and 9-14d); turquoise = down-regulated genes, red = up-regulated genes and yellow = unregulated genes. Red lines indicate inhibition and blue lines activation.
Figure 5Immunofluorescence cytochemistry images. A: control rats, B: 0.25h-4d, C: 5-8d and D: 9-14d. Yellow shows laminin, blue is DAPI and green cleaved caspase-3. Arrows in A and C show apoptotic myonucleus, arrow in B shows apoptotic nucleus outside laminin, arrow in D shows a centralized swelled nucleus that might be an activated satellite cell.